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Abstract
Up to 20% of patients with Crohn’s disease (CD) may have perianal fistula disease.
Classically, surgery has played an important role; in recent years, medical treatment
has taken a leading role. Immunosuppressants and biological trea tments have proven
beneficial in many patients, but still, the percentage of patients who do not respond
remains  significant.  In  this  scenario,  cell  therapy  is  envisaged  as  an  effective
alternative  to  surgery.  The  promising  preclinical  and clinical  data  that  we  review
below  suggest  that  cell  therapy  could  represent  a  major  advance  in  the  clinical
management of this difficult problem.
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1. Introduction
Up to 20% of patients with Crohn’s disease (CD) may have perianal fistula disease, which is
frequently  associated  with  perianal  collections  [1–3].  Classically,  surgery  has  played  an
important role, by the placement of drains or setons creation of ostomies, and in severe cases,
even proctectomy [4].  However,  in  recent  years,  medical  treatment  with  or  without  the
temporary  placement  of  drains  has  taken  a  leading  role.  Immunosuppressants  such  as
azathioprine, 6‐mercaptopurine, methotrexate and cyclosporine have proven beneficial in
many  patients.  In  more  complicated  cases  where  these  drugs  are  ineffective,  biological
treatments based on monoclonal antibodies have been shown to have some success for the
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induction and maintenance of remission of perianal fistula disease and associated proctitis [5–
11]. Still,  the percentage of patients who do not respond or do so only partially remains
significant. Furthermore, the existence of serious complications associated with treatment
should not be overlooked [9, 12, 13].
It is as a result of these inadequacies in current treatment strategies that cell therapy has arisen
as a complementary option [14]. The promising results published in recent years, both with
autologous and in allogeneic cells, highlight a need for greater understanding of the basic
principles of this new route and for clarification of the current state of the topic.
2. Basic concepts of cell therapy
Stem cells have both the capacity for self‐renewal or self‐replication and for production of
daughter cells that proceed along specific developmental pathways that will eventually lead
to differentiation into specialised cell types [15].
Embryonic stem cells are obtained from the inner cell mass of the embryo at the blastocyst
stage. They are able to generate cell lines derived from any of the three embryonic germ layers
(ectoderm, mesoderm and endoderm), giving them great therapeutic potential. In mature
adult tissues, we find adult multipotent stem cells, which are generally only able to renew and
regenerate tissues from the embryonic layer of which they come. However, based on the so‐
called phenomenon of cellular plasticity, in some instances, they can differentiate into cell
populations different to those of their embryonic origin, providing many therapeutic options
[16].
Finally, we have the so‐called induced pluripotent stem cells (iPS), which are somatic cells that
have been subjected to a process of nuclear reprogramming by ectopic expression of specific
transcription factors. These acquire molecular and functional characteristics of pluripotency
that make them akin to embryonic stem cells. They also display similar characteristics to these
in terms of morphology, proliferation, gene expression, epigenetic status of pluripotent genes
and their ability to differentiate in vivo and in vitro [17].
Although embryonic stem cells and iPS have great potential for cell‐based therapies, there are
several limitations to their use, including regulatory, ethical and genetic engineering consid‐
erations. As a result, there are currently no clinical trials evaluating their use [18].
On the other hand, adult stem cells can be obtained using much simpler methods and have no
restrictions or ethical considerations. Furthermore, because of their autologous origin, they are
not immunoreactive. Early studies using adult stem cells have focused on mesenchymal stem
cells (MSCs). These can be found in the stroma of virtually every organ, for example, in
subcutaneous adipose tissue and bone marrow. Being fibroblastoid cells, they are the precur‐
sors of all types of non‐haematopoietic connective tissues (bone, fat, cartilage, etc.). MSCs are
generally obtained by selection through adherence to tissue culture plastic, as they are able to
adhere and grow in conditions where other cell types do not usually proliferate [19]. They are
required to meet minimal criteria defined by the International Society for Cellular Therapy,
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namely, more than 95% of cells must express CD105, CD73 and CD90, as measured by flow
cytometry; and <2% must be positive for CD45, CD34, CD14, CD11b, CD79a or CD19 and
human leukocyte antigen (HLA) Class II. Moreover, they should be able to differentiate into
osteoblasts, chondroblasts and adipocytes under standard in vitro differentiation conditions
[20].
MSCs have a high capacity for proliferation and differentiation. Furthermore, under certain
experimental conditions, they have displayed the ability to differentiate into non‐connective
cell lineages, such as neuronal and endothelial. Finally, as a particularly interesting property
for the use at hand, they are capable, both in vitro and in vivo, of inhibiting immune response.
This ability to immunoregulate includes inhibition of the activation of T, B and NKcells, the
maturation of dendritic cells, as well as protecting against inflammatory and/or autoimmune
pathologies, including transplant rejection [21].
3. Mesenchymal stem cells as therapies
Early studies with adult stem cells focused on MSCs isolated from bone marrow stroma, which
have demonstrated adipogenic, osteogenic, chondrogenic, myogenic and neurogenic potential
in vitro. However, obtaining stem cells from this source is painful for the patient and only
provides a small number of cells [22]. Recently, methods of harvesting adult stem cells from
adipose tissue by simple liposuction have been developed. Adipose tissue is rich in such cells,
and their preparation is easier than that from bone marrow. Although there is some debate
about whether stem cells originate in the fat tissue itself, or if perhaps they are mesenchymal
or even peripheral blood stem cells passing through the fat, it is clear that adipose tissue
represents a valuable source of potentially useful stem cells. These adipose‐derived stem cells
(ASCs) have been shown to have an inherent ability to self‐renew, proliferate and differentiate
into mature tissues, depending on the microenvironment that surrounds them. Such charac‐
teristics, intrinsic to all stem cells, make them highly attractive for use in cell therapy and
regenerative medicine [23].
Interest in multipotent ASCs is increasing, owing to the ability to harvest large quantities of
tissue under local anaesthesia via the liposuction process. Indeed, from just 1 g of adipose
tissue, 5 × 103 stem cells can be obtained, which is much greater than the amount that can be
acquired from bone marrow. Furthermore, compared to bone marrow MSCs, in the early
stages, ASCs express CD34 to a greater extent (100–500 times higher) [24].
The terms adipose tissue‐derived stromal cell (ADSC), adipose stromal–vascular cell fraction
(SVF) and adipose‐derived regenerative cells (ADRC) all correspond to cells obtained imme‐
diately after digestion of adipose tissue by collagenase. On the other hand, the terms processed
lipoaspirate cells (PLA) and plastic‐adherent adipose‐derived stem cells (ASCS) describe those
that are obtained after culturing those produced by the digestion process. As a unifying term,
we refer to these cell types as adipose‐derived stem cells (ASC), in accordance with the
International Fat Applied Technology Society Consensus [25].
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4. Utilisation of MSCs in the treatment of perianal fistula disease
The precise mechanism of the therapeutic action of MSCs is not fully understood, but is like‐
ly to reflect their inherent characteristics, in particular their differentiation potential [26, 27].
MSCs have the ability to migrate to the site of a lesion or inflammatory process, stimulate
the proliferation and differentiation of resident stem cells through the secretion of growth
factors, remodel the matrix and exert an immunomodulatory and anti‐inflammatory effect.
Together, these properties aid help the healing of tissues [28–31]. It has also been demon‐
strated that MSCs can induce an increase in epithelialisation and angiogenesis through a
process of differentiation and paracrine interaction with skin cells [32–34].
Today, we know that Crohn’s disease delays T‐cell apoptosis [35, 36], and a mechanism of action
of ASCs when injected into the inflammation site in the fistula tract has been postulated.
Initially, the cells recognise proinflammatory cytokines such as IFN‐γ, followed by activation
of the indoleamine 2,3‐dioxygenase (IDO) enzyme, which is ultimately responsible for creating
a microenvironment—lymphocyte freezing by inhibition of phosphorylation. This results in a
reduction in the release of proinflammatory mediators (TNF‐α, IL‐6, etc.) and an increase in
that of anti‐inflammatory species such as IL‐10 [37].
5. Treatment protocol for anal fistulae
The protocol for stem cell treatment of anal fistulae inevitably starts with the harvesting of
the MSCs, either from the patient’s bone marrow or their fat (autologous), or from a healthy
donor (allogeneic). Bone marrow cells are harvested by aspiration, and then, the MSCs are
expanded ex vivo for subsequent use in the fistula tract [38, 39]. Although there are various
protocols for expansion and differentiation of cells obtained from adipose tissue (with a con‐
sequent variation in results), ASCs are normally used after digestion with collagenase under
constant stirring. The obtained solution is then centrifuged at low speed, and the resultant is
filtered through a nylon mesh of 40–200 μm. The new solution is then centrifuged again, and
the cells are re‐suspended in fresh expansion medium. It is important to stress that this pro‐
cedure must be carried out in extremely sterile conditions [40].
As for the route of administration, there is a single study in which allogeneic bone marrow
MSCs were given intravenously, with the closure of fistulas being a secondary objective of the
study [41]; all other published studies have employed the intralesional route [38, 39, 42–50].
Before intralesional injection of the isolated MSCs, the lesion site must be prepared with
similarly intensive curettage, avoiding the use of cytolytic substances (hydrogen peroxide).
The inner fistula orifice can then be sealed with an absorbable suture. At this point, half of the
cell preparation is administered to the tissue around the inner hole, making small submucosal
wheals. The other half is applied along the walls of the fistula tract, if possible along its whole
length, while taking care not to go deeper than a few millimetres, again in small wheals
(Figure 1). Several studies have investigated the use of fibrin glue as an adjuvant or scaffold,
in order to enhance the attachment of cells in the fistula tract [43, 45–47]. The dose of cells
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required for optimum results remains to be determined; in published studies, this ranges from
3.5 × 106 to 40 × 106 cells [39–50].
Figure 1. Implant points. (a) Wheal in the internal fistula orifice; (b) injection in the fistula tract at a depth of no more
than 2 mm (courtesy of Tigenix).
Most studies have used ASCs, but there are also some that have evaluated the use of bone
marrow cells. As for the cell source, the advantages of an allogeneic source (from healthy
donors) are innumerable in comparison with those of an autologous source, especially in terms
of greater accessibility, easy expandability and good stability. Their use is possible because of
their low immunogenicity and limited persistence, which reduce the chances of provoking an
adverse effect in the host [51].
6. Safety and efficacy of MSCs in the treatment of anal fistulae
The first experience with stem cells in the treatment of anal fistulae was reported by García‐
Olmo et al. [52]. Several studies have since been published, the majority of which are from
Spanish groups. The MSCs used have mainly originated from adipose tissue, with only two
studies using bone marrow MSCs. In these latter cases, both allogeneic and autologous cells
have been used. In all studies, administration was intralesional, with fibrin glue often used [38,
39].
Today, any questions as to the feasibility and safety of such treatment seem to have been
resolved, at least within the range of doses used. A retrospective study evaluating whether
MSC treatment has any influence on fertility, course of pregnancy, birthweight or physical
status was recently published [53]. Five patients with fistula associated with Crohn’s disease
treated with ASCs, and who indicated their intention to have children after completion of
treatment, were tracked. Fertility and pregnancy course were not found to be affected by this
therapy. Furthermore, no treatment‐related malformations in newborns were observed.
Therefore, it was concluded that in the patients analysed in the study, local injection of ASCs
was not associated with adverse effects on the ability to conceive, pregnancy course or the
newborn’s condition.
In the published literature, there are differences in cure rate depending on the follow‐up, but
in general, it is estimated to be between 50 and 70% (Table 1).
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Authors, year Study design Source of cells Results
Garcia‐Olmo et al., 2005
(Spain) [42]
Phase I clinical study (n = 4) ASCs (autologous) Complete closure: 50% of
patients; 75% fistulas
Garcia‐Olmo et al., 2009
(Spain) [42]
Open‐label, multicenter, phase II
study (n = 14)
ASCs (autologous);
fibrin glue
Fistula healing: 71 vs 14%
Ciccocioppo et al., 2011
(Italy) [38]
Prospective study (n = 10) MSCs (autologous) Reduction in CDAI, PDAI and
pain/discharge PDAI scores
Guadalajara et al., 2012
(Spain) [43]
Retrospective follow‐up of Garcia‐
Olmophase II study (n = 5)
ASCs (autologous);
fibrin glue
58% sustained fistula closure at
end of follow‐up by mean
3 years No safety problem
Cho et al., 2013
(Korea) [47]
Open‐label, multicentre, dose
escalationphase I study (n = 10)
ASCs (autologous);
fibrin glue
Healing in 50% in the group
with 2 × 107 cells
Lee et al., 2013
(Korea) [45]
Open‐label, multicentre, phase II
study (n = 42; 33 completed
follow‐up)
ASCs (autologous);
fibrin glue
Fistula closure in 79%, recidive
11%
de la Portilla et al., 2013
(Spain) [48]
Open‐label pilot study (n = 24) ASCs (allogeneic) Complete closure: 56.3% at 24 
weeks
Ciccocioppo et al., 2015
(Italy) [44]
5‐year follow‐up of 2011 study
(n = 10)
MSCs (autologous) 37% fistula relapse‐free 4 years
later
Cho et al., 2013
(Korea) [46]
Retrospective, 1‐year follow‐up
from 2013 study
ASCs (autologous);
fibrin glue
Complete closure maintained
in 75% at 2 years ITT analysis;
80% PP analysis
Garcia‐Olmo et al., 2015
(Spain) [49]
Retrospective, open‐label
(n = 3 with CD)
ASCs (allogeneic
andautologous)
Healing in 2/3 CD fistula
patients
Molendijk et al., 2015
(The Netherlands) [39]
Double‐blind, placebo‐
controlledphase II study (n = 21)
MSCs (allogeneic) Healing up to 85%
Park et al., 2015
(Korea) [50]
Multicentre, open‐label, dose
escalation pilot study (n = 6)
ASCs (allogeneic);
fibrin glue
Group 1 (1 × 107 cells/ml);
healing 100% Group 2 (3 × 107 
cells/ml); healing 100%
ASCs, adipose‐derived stem cells; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; ITT, intention to treat; IV,
intravenous; MSCs, mesenchymal stem cells/mesenchymal stromal cells; PDAI, Pouchitis disease activity index; PP, per
protocol; SC, stem cells.
Table 1. Published studies using MSCs to treat Crohn’s disease patients with perianal fistulas.
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Ciccocioppo et al. evaluated the long‐term safety and efficacy of the use of bone‐marrow‐
derived MSCs. In their study, 8 patients were followed prospectively for 72 months. These
patients were part of a phase I/II trial previously conducted, in which a cure rate of 70% per
year was reported, with improvement observed in the remaining 30% [44]. Patients received
serialised injections of MSCs (4 on average) at intervals of 4 weeks. Secondary endpoints were
the time patients remained without fistula and the time they were free of medical or surgical
treatment. The Chrohn’s Disease Activity Index (CDAI) increased over the first 2 years,
followed by a gradual decline in the third year, and stabilisation at the end of follow‐up at
figures similar to those of the first year. The probability of remaining without fistula was 88%
for the first year, 50% at 2 years and 37% over the next 4 years. The probability of patients being
free from surgery was 100% for the first year, 75% for years 2–4 and 63% at years 5 and 6. Finally,
the probability of patients being free from medical treatment was 88% for the first year, 25%
at years 2–4 and 25% at years 5 and 6. No adverse effects related to treatment in these follow‐
up periods were recorded. The authors conclude that the fact that the activity indices increase
again in the second year might suggest that this therapy is not curative, but that it does improve
the remission rate in patients with refractory disease. Moreover, almost all patients required
the reintroduction of biological or immunosuppressive therapy after the second year [44].
We are currently awaiting the publication of the results of a phase III, randomised, placebo,
double‐blind, multicentre, and international clinical trial employing Cx601, a preparation of
allogeneic ASCs. It has recently been reported that, after 24 weeks, Cx601 was statistically
superior to placebo in achieving the combined response (clinical and imaging) of complex
perianal fistulas in Crohn’s disease patients whose response to previous treatment, including
anti‐TNFs, had been inadequate.
7. Future perspectives
There is no doubt that a new avenue has opened for the treatment of Crohn’s disease patients
suffering from fistulae refractory to conventional therapy. Since the first description of the
treatment, interest in this therapy has grown, so that in addition to the 11 studies published
to date, at the time we write this chapter, there are more than a dozen clinical trials in recruit‐
ment or in the results publication phase.
While the safety of ASC therapy seems to have been well established, the optimal dosage, route
of administration (intravenous versus intralesional), administration technique (alone or
together with fibrin glue), among other matters, are yet to be adequately determined. However,
these should be investigated and resolved in the coming years.
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